Zura Bio (NASDAQ:ZURA) Price Target Cut to $10.00 by Analysts at Chardan Capital

Zura Bio (NASDAQ:ZURA) had its target price cut by Chardan Capital from $12.00 to $10.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the stock. Chardan Capital also issued estimates for Zura Bio’s FY2025 earnings at ($0.77) EPS and FY2026 earnings at ($0.78) EPS.

A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Zura Bio Stock Down 6.6 %

Shares of NASDAQ:ZURA opened at $1.27 on Wednesday. The company has a 50 day moving average of $1.46 and a two-hundred day moving average of $2.73. Zura Bio has a 52-week low of $1.07 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. Research analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Large investors have recently modified their holdings of the stock. Two Sigma Advisers LP bought a new stake in Zura Bio in the fourth quarter valued at about $32,000. Shay Capital LLC acquired a new position in shares of Zura Bio in the 4th quarter worth approximately $233,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the 4th quarter worth approximately $35,000. Millennium Management LLC increased its holdings in shares of Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after acquiring an additional 657,420 shares during the last quarter. Finally, Forefront Analytics LLC raised its position in shares of Zura Bio by 74.4% during the 4th quarter. Forefront Analytics LLC now owns 53,734 shares of the company’s stock valued at $134,000 after acquiring an additional 22,924 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.